# China NMPA Drug Inspection - Jilin Shuangxing Pharmaceutical Co., Ltd. - Acanthopanax senticosus tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/jilin-shuangxing-pharmaceutical-co-ltd/fe676ca9-72c1-4551-ad2f-245ec726ac17/
Source feed: China

> China NMPA drug inspection for Jilin Shuangxing Pharmaceutical Co., Ltd. published May 16, 2018. Drug: Acanthopanax senticosus tablets. The National Medical Products Administration (NMPA) of China announced on May 16, 2018, that four batches of drugs from 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 28 of 2018 from the National Medical Products Administration regarding four batches of drugs that did not meet the requirements.
- Company Name: Jilin Shuangxing Pharmaceutical Co., Ltd.
- Publication Date: 2018-05-16
- Drug Name: Acanthopanax senticosus tablets
- Inspection Finding: The non-compliant item is content determination.
- Action Taken: Control measures such as sealing and seizing were taken, sales and use were suspended, products were recalled, rectification was carried out, and an investigation was launched.
- Summary: The National Medical Products Administration (NMPA) of China announced on May 16, 2018, that four batches of drugs from multiple companies failed to meet regulatory standards based on tests by provincial drug control institutes. The announcement, dated May 15, 2018, detailed non-compliance from several manufacturers. Shaohuatang Pharmaceutical Co., Ltd., along with another company, produced Angelica dahurica found to have excessive sulfur dioxide residue. Additionally, Hubei Renyue Pharmaceutical Co., Ltd.'s Andrographis paniculata tablets and Jilin Shuangxing Pharmaceutical Co., Ltd.'s Acanthopanax senticosus tablets both failed content determination, indicating issues with their active ingredient levels. In response, regulatory authorities initiated immediate control measures, including product sealing and seizure. The affected companies were mandated to halt sales, recall products, and implement corrective actions. Operating under the *Drug Administration Law of the People's Republic of China* (Articles 73, 74, 75), the NMPA directed provincial drug regulatory bodies to investigate these companies for potential illegal activities related to producing or selling substandard drugs. These investigations are required to be completed, and their findings made public, within three months of receiving the inspection reports. The announcement also outlines procedures for companies to object to product authenticity and for authorities to trace problematic product sources.

Company: https://www.globalkeysolutions.net/companies/jilin-shuangxing-pharmaceutical-co-ltd/15164930-890b-44b4-8751-3b29d4acdfb4/